Gene · 4070
Papers3,230
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
441 to 460 of 3,230
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Engineered Nanobody-Bearing Extracellular Vesicles Enable Precision Trop2 Knockdown in Resistant Breast Cancer. | Pharmaceutics | 2025 | 41155954 | PubTator, text mining | PubMed |
| Surface Engineering of Natural Killer Cells with Lipid-Based Antibody Capture Platform for Targeted Chemoimmunotherapy. | Pharmaceutics | 2025 | 41155922 | PubTator, text mining | PubMed |
| Therapeutic efficacy of sacituzumab govitecan in recurrent refractory germ cell tumors. | Biomed Pharmacother | 2025 | 41138655 | PubTator, text mining | PubMed |
| TROP-2-targeted antibody-drug conjugate SHR-A1921 for advanced or metastatic solid tumors: A first-in-human phase 1 study. | Cancer Cell | 2025 | 41135519 | PubTator, text mining | PubMed |
| Psoriasis and lichen planus: an immunohistochemical study of Trophoblast cell-surface antigen 2 expression in skin biopsies. | Hum Cell | 2025 | 41128810 | PubTator, text mining | PubMed |
| Efficacy and safety of antibody-drug conjugate combination therapy in advanced urothelial carcinoma. | Front Oncol | 2025 | 41127009 | PubTator, text mining | PubMed |
| Chemotherapeutic Drug-Antibody Conjugates (ChemoBodies): Recent Advances and Future Directions. | Curr Oncol Rep | 2025 | 41123838 | PubTator, text mining | PubMed |
| Antibody-drug conjugates in the treatment of advanced triple-negative breast cancer. | Prz Menopauzalny | 2025 | 41114412 | PubTator, text mining | PubMed |
| Comparative immunohistochemical expression of TROP2 in brain metastatic and primary tumors. | Am J Cancer Res | 2025 | 41113987 | PubTator, text mining | PubMed |
| Preclinical Evaluation of a Trop2-Targeted Peptide Probe for PET Imaging of Triple-Negative Breast Cancer. | Anal Chem | 2025 | 41105928 | PubTator, text mining | PubMed |
| Trophoblast cell-surface antigen 2 expression in digestive neoplasms: a promising target for antibody-drug conjugates. | Oncologist | 2025 | 41100061 | PubTator, text mining | PubMed |
| Prognostic relevance of TROP2 expression in patients with non-small cell lung cancer receiving immunotherapy. | Sci Rep | 2025 | 41073519 | PubTator, text mining | PubMed |
| Highlights of ASCO 2025. | Oncologist | 2025 | 41056448 | PubTator, text mining | PubMed |
| Expression and therapeutic potential of TROP2 in cisplatin-resistant germ cell tumors. | J Cancer Res Clin Oncol | 2025 | 41055771 | PubTator, text mining | PubMed |
| Comparison of molecular profiles (Nectin-4 and TROP-2) in upper tract urothelial carcinoma with a positive history of urinary bladder cancer vs. UTUC only in the era of ADCs. | BMC Cancer | 2025 | 41053655 | PubTator, text mining | PubMed |
| Antibody drugs conjugates in non-small cell lung cancer: current status and challenges. | Oncologist | 2025 | 41052301 | PubTator, text mining | PubMed |
| Antibody drugs conjugates in small-cell lung cancer: present-day status and promises. | Oncologist | 2025 | 41052285 | PubTator, text mining | PubMed |
| Population Pharmacokinetic Analysis of Datopotamab Deruxtecan (Dato-DXd), a TROP2-Directed Antibody-Drug Conjugate, in Patients With Advanced Solid Tumors. | CPT Pharmacometrics Syst Pharmacol | 2025 | 41035281 | PubTator, text mining | PubMed |
| Survival outcomes and the role of DNADX ctDNA testing in patients treated with sacituzumab govitecan for metastatic breast cancer. | ESMO Open | 2025 | 41033284 | PubTator, text mining | PubMed |
| The potential of antibody-drug conjugates in immunotherapy for non-small cell lung cancer: current progress and future. | Front Oncol | 2025 | 41030952 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/4070/papers?page=23